David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block
BACKGROUND: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis. METHODS: This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, 'switch' study from cinacalcet to etelcalcetide...
October 1, 2020: Nephrology, Dialysis, Transplantation